Inclusion Criteria

1. Patient selection criteria

- Female aged equal or more than 65 years.

- Histological diagnosis of early BC for which the treating physician considers
(neo) adjuvant chemotherapy to be beneficial. Recommended situations are:

- Triple negative BC if pT > 1cm.

- HER-2 positive BC if pT1 > 1cm; and trastuzumab will be given after study
chemotherapy.

- "Luminal B" cancers defined as ER+, PgR + or neg, Ki-67 ≥ 14%, and pT1 > 1cm.

- "Luminal A" cancers (ER+, PgR+ and Ki-67 < 14%) will be considered only if ≥ 4
nodes.

- Poor response to a preoperative endocrine therapy.

- WHO performance status equal or less than 1.

- Baseline LVEF equal or more than 50% measured by echocardiography.

- Adequate organ function including:

- neutrophils more or equal to 1.5 x 109/L.

- platelets more or equal to100 x 109/L.

- bilirubin < 1.25 x upper limit of normal (ULN) for the institution.

- transaminases: AST < 2.5 x ULN , ALT < 2.5 x ULN and alkaline phosphatase ≤ 2.5
x ULN for the institution.

- Estimated creatinine clearance > 30ml/min (using the Crockoft and Gault formula)
(See Appendix E) .

- No previous exposure to chemotherapy in this neoadjuvant or adjuvant setting.

- No serious cardiac illness or medical conditions as judged by the investigator
including, but not confined to:Symptomatic ventricular arrhythmias,Clinical
and/or ECG evidence of myocardial infarction within the last 12 months,Coronary
artery disease requiring medication,High-risk uncontrolled arrhythmias,Poorly
controlled hypertension (e.g. systolic >180 mm Hg or diastolic >100 mm Hg).

- Other concurrent serious diseases that may interfere with planned treatment
including severe pulmonary conditions/illness.

- No participation to other clinical trials involving therapeutic agents within
the 6 weeks prior to the randomization.

- No prior or concurrent diagnosis of cancer, except for adequately treated
basocellular and squamous cell carcinoma of the skin or cervical uterine in situ
tumor

- Absence of any psychological, familial, sociological or geographical condition
potentially hampering compliance with the study protocol and follow-up schedule;
those conditions should be discussed with the patient before registration in the
trial.

- Signed written informed consent must be given according to ICH-GCP and
national/local regulations, prior to any study specific screening procedures and
randomization.

2. Caregiver selection criteria

- to be identified by participating patients as their primary caregivers i.e the
person who helps them the most to cope with cancer in their everyday life

- to be at least eighteen years old

- to be aware of the cancer diagnosis of the patients to be fit enough to complete
the questionnaires

- to be French speaking

- to be free of any cognitive dysfunction.

- to give their written informed consent as regards participation in the study.